{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T02:07:27Z","timestamp":1769134047079,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":1027,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"DOI":"10.1164\/rccm.202212-2262ed","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:14:45Z","timestamp":1673446485000},"page":"816-818","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":2,"title":["Promise and Peril of Pretomanid\u2013Rifamycin Regimens for Drug-susceptible Tuberculosis"],"prefix":"10.1093","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-0692","authenticated-orcid":false,"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"first","affiliation":[{"name":"UCSF Center for Tuberculosis"},{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":false,"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[{"name":"UCSF Center for Tuberculosis"},{"name":"Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"2026012204493082100_bib1","author":"World Health Organization","year":"2022"},{"key":"2026012204493082100_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012204493082100_bib3","year":"2022"},{"key":"2026012204493082100_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012204493082100_bib5","doi-asserted-by":"crossref","first-page":"e0239821","DOI":"10.1128\/aac.02398-21","article-title":"Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and\/or OPC-167832 in murine tuberculosis models","volume":"66","author":"Tasneen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204493082100_bib6","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.00686-08","article-title":"Enhanced bactericidal activity of rifampin and\/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis","volume":"52","author":"Tasneen","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204493082100_bib7","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204493082100_bib8","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026012204493082100_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/rccm.202208-1475OC","article-title":"Assessing pretomanid for tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive TB: 12-week results","volume":"207","author":"Dooley","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204493082100_bib10","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2026012204493082100_bib11","doi-asserted-by":"crossref","first-page":"e01196-20","DOI":"10.1128\/AAC.01196-20","article-title":"Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis","volume":"65","author":"Ignatius","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204493082100_bib12","first-page":"CD005159","article-title":"Rifabutin for treating pulmonary tuberculosis","volume":"2007","author":"Davies","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012204493082100_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012204493082100_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012204493082100_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5588\/ijtld.20.0513","article-title":"A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB","volume":"25","author":"Tweed","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012204493082100_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJMe2000860","article-title":"Triumph and tragedy of 21st century tuberculosis drug development","volume":"382","author":"Thwaites","year":"2020","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/207\/7\/816\/66438483\/ajrccm_207_7_816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/207\/7\/816\/66438483\/ajrccm_207_7_816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:49:42Z","timestamp":1769075382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/207\/7\/816\/8428286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202212-2262ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"2023-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}